- Home
- CREV vs GRI Comparison
CREV vs GRI Comparison
Compare CREV & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- GRI
- Stock Information
- Founded
- CREV 2007
- GRI 2018
- Country
- CREV Ireland
- GRI United States
- Employees
- CREV N/A
- GRI N/A
- Industry
- CREV
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- GRI Health Care
- Exchange
- CREV Nasdaq
- GRI Nasdaq
- Market Cap
- CREV 6.0M
- GRI 4.8M
- IPO Year
- CREV N/A
- GRI N/A
- Fundamental
- Price
- CREV $4.18
- GRI $1.99
- Analyst Decision
- CREV
- GRI Strong Buy
- Analyst Count
- CREV 0
- GRI 2
- Target Price
- CREV N/A
- GRI $22.50
- AVG Volume (30 Days)
- CREV 23.2K
- GRI 3.4M
- Earning Date
- CREV 05-14-2025
- GRI 11-13-2025
- Dividend Yield
- CREV N/A
- GRI N/A
- EPS Growth
- CREV N/A
- GRI N/A
- EPS
- CREV N/A
- GRI N/A
- Revenue
- CREV $39,261,077.00
- GRI N/A
- Revenue This Year
- CREV $40.76
- GRI N/A
- Revenue Next Year
- CREV $86.18
- GRI N/A
- P/E Ratio
- CREV N/A
- GRI N/A
- Revenue Growth
- CREV 41.52
- GRI N/A
- 52 Week Low
- CREV $2.00
- GRI $1.10
- 52 Week High
- CREV $12.75
- GRI $30.43
- Technical
- Relative Strength Index (RSI)
- CREV 49.77
- GRI 56.90
- Support Level
- CREV $4.10
- GRI $1.86
- Resistance Level
- CREV $4.44
- GRI $2.10
- Average True Range (ATR)
- CREV 0.29
- GRI 0.14
- MACD
- CREV -0.00
- GRI -0.01
- Stochastic Oscillator
- CREV 24.11
- GRI 52.23
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.